Airbus Cancels Remaining Qatar A350 Orders: Report
Airbus SE (OTC:EADSY) revoked all remaining A350 orders from Qatar Airways, raising the stakes in safety and contractual dispute…
Caterpillar To Pay No Penalties As Settlement Of Tax Dispute
In an SEC filing, Caterpillar Inc (NYSE:CAT) revealed settling with the U.S. Internal Revenue Service (IRS), which resolves all issues…
FDA Warns of Clip Lock Malfunctions With Abbott’s MitraClip Heart Valve Devices
The FDA alerted healthcare providers about the potential for clip lock malfunctions with Abbott Laboratories (NYSE: ABT) MitraClip's delivery system to stop heart valve leakage.
Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder
Cara Therapeutics Inc (NASDAQ:CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia…
Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial
Vistagen Therapeutics Inc (NASDAQ:VTGN) completed an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an…
Cantor Fitzgerald Initiates Coverage On This ‘Attractively Valued’ MedTech Stock
Cantor Fitzgerald initiated coverage on Asensus Surgical Inc (NYSE:ASXC) with an Overweight rating and a price target of $1.50. ASXC is a…
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating…
With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
Cantor Fitzgerald initiated coverage on Actinium Pharmaceuticals Inc (NYSE:ATNM) with an Overweight rating and a price target of $20, almost an upside…
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
Exelixis Inc (NASDAQ:EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced…
Gilead’s Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
Gilead Sciences Inc (NASDAQ:GILD) announced the overall survival (OS) results from the Phase 3 TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus…